TY - JOUR
T1 - Lewy body dementias
AU - Walker, Zuzana
AU - Possin, Katherine L.
AU - Boeve, Bradley F.
AU - Aarsland, Dag
N1 - Funding Information:
ZW has received personal fees from GE Healthcare, Bayer Healthcare, and Novartis; grants from GE Healthcare and Lundbeck; and her National Health Service employer received reimbursement for her time in connection to a phase 4 trial from GE Healthcare, outside the submitted work. KLP has received grants from the US National Institute on Ageing, Michael J Fox Foundation, Center for Medicare and Medicaid Innovation, and the Hellman Family Foundation; contract with Quest Diagnostics; and personal fees from Acupera. BFB has received grants from Cephalon, Allon Pharmaceuticals, FORUM Pharmaceuticals, GE Healthcare; and personal fees from Cambridge Medicine, the American Academy of Neurology, and Tau Consortium, all outside the submitted work. DA has received grants from GE Healthcare, and personal fees from Novartis and H Lundbeck, outside the submitted work.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/10/24
Y1 - 2015/10/24
N2 - The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.
AB - The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.
UR - http://www.scopus.com/inward/record.url?scp=84945394119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945394119&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(15)00462-6
DO - 10.1016/S0140-6736(15)00462-6
M3 - Review article
C2 - 26595642
AN - SCOPUS:84945394119
SN - 0140-6736
VL - 386
SP - 1683
EP - 1697
JO - The Lancet
JF - The Lancet
IS - 10004
ER -